Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
Marinus Pharmaceuticals, Inc. (MRNS)
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.marinuspharma.com/investor-relations
Company Research
Source: GlobeNewswire
RADNOR, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that results from its Phase 2 trial of ganaxolone in Refractory Status Epilepticus (RSE) were presented at the Neurocritical Care Society 17th Annual Meeting in Vancouver, BC. The results were featured in an oral platform presentation by Henri Vaitkevicius M.D., investigator in the study. As previously disclosed, ganaxolone met the primary endpoint in the study with none of the 17 patients progressing to IV anesthetics within 24 hours of treatment initiation. A target dose of ganaxolone has been identified for advancement to Phase 3 and this is supported by pharmacokinetic (PK) data, presented for the first time at the meeting today. The newly presented PK data show that the target dose of ganaxolone (7
Show less
Read more
Impact Snapshot
Event Time:
MRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNS alerts
High impacting Marinus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MRNS
News
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
MRNS
Earnings
- 11/12/24 - Beat
MRNS
Sec Filings
- 12/23/24 - Form 8-K
- 12/10/24 - Form 8-K
- 12/10/24 - Form 144
- MRNS's page on the SEC website